tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ZYME Stock Latest News

Strategic Shift to Zanidatamab Drives Optimistic Buy Rating for Zymeworks
RatingsStrategic Shift to Zanidatamab Drives Optimistic Buy Rating for Zymeworks
10d ago
ZYME
Strategic Focus and Promising Pipeline Drive Buy Rating for Zymeworks
PremiumRatings
Strategic Focus and Promising Pipeline Drive Buy Rating for Zymeworks
11d ago
ZYME
Zymeworks Discontinues ZW171 Development Amidst Strategic Pipeline Focus
PremiumCompany Announcements
Zymeworks Discontinues ZW171 Development Amidst Strategic Pipeline Focus
12d ago
ZYME
Zymeworks to discontinue clinical development of ZW171
PremiumThe Fly
Zymeworks to discontinue clinical development of ZW171
12d ago
ZYME
Zymeworks to Engage in Key Investor Conferences
PremiumCompany Announcements
Zymeworks to Engage in Key Investor Conferences
26d ago
ZYME
Zymeworks Earnings Call: Revenue Surge and Strategic Gains
PremiumCompany AnnouncementsZymeworks Earnings Call: Revenue Surge and Strategic Gains
1M ago
ZYME
Zymeworks Strengthens Leadership with New Board Appointments
Premium
Company Announcements
Zymeworks Strengthens Leadership with New Board Appointments
1M ago
ZYME
Zymeworks price target raised to $22 from $19 at Citi
Premium
The Fly
Zymeworks price target raised to $22 from $19 at Citi
1M ago
ZYME
Zymeworks Reports Strong Q2 2025 Financial Performance
PremiumCompany Announcements
Zymeworks Reports Strong Q2 2025 Financial Performance
1M ago
ZYME
Zymeworks: Strong Financial Performance and Promising Pipeline Drive Buy Rating
PremiumRatings
Zymeworks: Strong Financial Performance and Promising Pipeline Drive Buy Rating
1M ago
ZYME
Zymeworks’ Strategic Financial Management and Promising Pipeline Drive Buy Rating
PremiumRatings
Zymeworks’ Strategic Financial Management and Promising Pipeline Drive Buy Rating
1M ago
ZYME
Zymeworks reports Q2 EPS 3c, consensus (46c)
PremiumThe Fly
Zymeworks reports Q2 EPS 3c, consensus (46c)
1M ago
ZYME
Zymeworks Reports Q2 Results and FDA Clearance
PremiumCompany AnnouncementsZymeworks Reports Q2 Results and FDA Clearance
1M ago
8K
ZYME
Zymeworks: Promising Pipeline and Strategic Advancements Drive Buy Rating
Premium
Ratings
Zymeworks: Promising Pipeline and Strategic Advancements Drive Buy Rating
2M ago
ZYME
Zymeworks’ ZW251 Receives FDA Clearance for Clinical Trials in Liver Cancer
Premium
Company Announcements
Zymeworks’ ZW251 Receives FDA Clearance for Clinical Trials in Liver Cancer
2M ago
ZYME
Zymeworks announces FDA clearance of IND application for ZW251
PremiumThe Fly
Zymeworks announces FDA clearance of IND application for ZW251
2M ago
ZYME
Zymeworks to Announce Q2 2025 Financials and Engage in Investor Conferences
PremiumCompany Announcements
Zymeworks to Announce Q2 2025 Financials and Engage in Investor Conferences
2M ago
ZYME
Positive Buy Rating for Zymeworks Amid Promising Clinical Trials and Strategic Partnerships
PremiumRatings
Positive Buy Rating for Zymeworks Amid Promising Clinical Trials and Strategic Partnerships
2M ago
ZYME
Zymeworks: Hold Rating Amid Uncertain Market Potential and Upcoming Catalysts
PremiumRatings
Zymeworks: Hold Rating Amid Uncertain Market Potential and Upcoming Catalysts
2M ago
ZYME
Zymeworks Gains Momentum with European Approval and Promising Financial Milestones for Zanidatamab
PremiumRatingsZymeworks Gains Momentum with European Approval and Promising Financial Milestones for Zanidatamab
2M ago
ZYME
Zymeworks Amends Warrant Agreement with EcoR1 Capital
Premium
Company Announcements
Zymeworks Amends Warrant Agreement with EcoR1 Capital
3M ago
8K
ZYME
Zymeworks’ Promising Clinical Developments and Strategic Positioning Justify Buy Rating
Premium
Ratings
Zymeworks’ Promising Clinical Developments and Strategic Positioning Justify Buy Rating
3M ago
ZYME

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >